In April 2024, the Drug examination Center of the State Drug Administration (CDE) accepted a total of 2 new stem cell-related drugs with implied clinical license.

Shanghai Changzheng Hospital completed the world's first case of type 2 diabetes treated with islet tissue derived from in vivo embryonic stem cells, stopping insulin in March, acarbose in December and metformin in 14 months.

Cell：Establishment of 4R tau lesion model using human induced pluripotent stem cells

Shenyang successfully obtains "international visa" for cord blood and adult stem cells

Heart failure patients saved! In Japan, iPSCs "heart spheres" are injected into the damaged heart with perfect integration and strong pumping ability, without the risk of arrhythmia